The treated natural history of high risk superficial bladder cancer: 15-year outcome

The Journal of Urology
M S CooksonW R Fair

Abstract

The long-term outcome of patients with high risk superficial bladder cancer is unknown. We report the results of 15 years of followup of high risk patients treated initially with aggressive local therapy, including transurethral resection alone or combined with intravesical bacillus Calmette-Guerin. Between 1978 and 1981, 86 high risk patients enrolled in a randomized study of transurethral resection alone or with intravesical bacillus Calmette-Guerin for superficial bladder cancer. Of these patients 81% had diffuse carcinoma in situ and 44% had stage T1 tumors before entry into the study. Patients were followed until death (61%) or until the present time (median followup 184 months). Disease stage progressed in 46 patients (53%) and 31 (36%) eventually underwent cystectomy for progression (28) or refractory carcinoma in situ (3), while 18 (21%) had upper tract tumors at a median of 7.3 years. The 10 and 15-year disease specific survival rates were 70 and 63%, respectively. At 15 years 34% of patients overall were dead of bladder cancer, 27% were dead of other causes and 37% were alive, including 27% with an intact functioning bladder. Despite aggressive local therapy patients with high risk superficial bladder cancer are at li...Continue Reading

References

Apr 1, 1992·The Journal of Urology·H W HerrH F Oettgen
Dec 1, 1987·The Journal of Urology·H W HerrW F Whitmore
Sep 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H W HerrW F Whitmore
Jul 1, 1985·The Journal of Urology·D L Lamm
Jun 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H W HerrH F Oettgen
Aug 1, 1994·The Journal of Urology·H W Herr
Jan 1, 1994·The Journal of Urology·C L AmlingD F Paulson
Jan 1, 1993·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J A WitjesF M Debruyne

❮ Previous
Next ❯

Citations

Feb 4, 2005·Der Urologe. Ausg. A·K Miller, R Hautmann
Aug 7, 2007·Der Urologe. Ausg. A·M MayM Siegsmund
Oct 12, 2012·Applied Microbiology and Biotechnology·Karine Rech BegniniFabiana Kömmling Seixas
Mar 14, 2009·International Urology and Nephrology·José I López, Javier C Angulo
Sep 4, 2008·Current Urology Reports·John P Stein, David F Penson
Mar 26, 2004·European Urology·Bernard Malavaud
Mar 26, 2004·European Urology·Bernard Gattegno
Oct 11, 2003·Urology·John P Stein
Dec 1, 2000·The Urologic Clinics of North America·M E Jabbour, A D Smith
Jun 21, 2002·European Urology·Willem OosterlinckUNKNOWN European Association of Urology (EAU) Working Group on Oncological Urology
Dec 13, 2002·European Urology·Dominique K Chopin, Bernard Gattegno
Jun 20, 2003·European Urology·F MayH Schwaibold
Feb 14, 2002·Critical Reviews in Oncology/hematology·Filippo de BraudCora N Sternberg
Sep 25, 2002·Critical Reviews in Oncology/hematology·Jason GeeH Barton Grossman
Jul 10, 2003·Critical Reviews in Oncology/hematology·Richard J Cote, Ram H Datar
Jun 28, 2000·Urologic Oncology·H W Herr
Sep 6, 2000·Urologic Oncology·C A ReznikoffM A Newton
Jun 18, 2003·Urologic Oncology·Ralph A HighshawRalph W deVere White
Jul 31, 2004·Urologic Oncology·Fernando J BiancoDavid P Wood
Mar 13, 2010·Actas urologicas españolas·J HuguetH Villavicencio
Feb 14, 2006·Nature Clinical Practice. Urology·Brent K Hollenbeck, James E Montie
Jul 21, 2011·Carcinogenesis·Koji NishizawaOsamu Ogawa
Feb 28, 2013·Japanese Journal of Clinical Oncology·Ei-ichiro TakaokaHiroyuki Nishiyama
Apr 17, 2003·Journal of the National Cancer Institute·Deborah SchragColin B Begg
Apr 9, 2009·Journal of the National Cancer Institute·Gary H LymanStephen J Freedland
Feb 11, 2003·The Journal of Urology·Christian PfisterJean-Jacques Rambeaud
Jun 11, 2005·The Journal of Urology·Jonathan E RosenbergEric J Small
Jan 12, 2012·TheScientificWorldJournal·A Karim Kader

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.